Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

多奈哌齐 安慰剂 医学 阿尔茨海默病 内科学 日常生活活动 随机对照试验 痴呆 心理学 精神科 疾病 病理 替代医学
作者
Carol A. Courtney,Dawn Farrell,Richard Gray,Robert Kerrin Hills,Leila Lynch,E Sellwood,SJ Edwards,Wendy Hardyman,James Raftery,Peter Crome,Corinne Lendon,Helen A. Shaw,Peter Bentham
出处
期刊:The Lancet [Elsevier]
卷期号:363 (9427): 2105-2115 被引量:788
标识
DOI:10.1016/s0140-6736(04)16499-4
摘要

SummaryBackgroundCholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long?Methods565 community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind treatment continuing as long as judged appropriate. Primary endpoints were entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities on the Bristol activities of daily living scale (BADLS). Outcome assessments were sought for all patients and analysed by logrank and multilevel models.FindingsCognition averaged 0·8 MMSE (mini-mental state examination) points better (95% Cl 0·5–1·2; p<0·0001) and functionality 1·0 BADLS points better (0·5–1·6; p<0·0001) with donepezil over the first 2 years. No significant benefits were seen with donepezil compared with placebo in institutionalisation (42% vs 44% at 3 years; p=0·4) or progression of disability (58% vs 59% at 3 years; p=0·4). The relative risk of entering institutional care in the donepezil group compared with placebo was 0·97 (95% Cl 0·72–1·30; p=0·8); the relative risk of progression of disability or entering institutional care was 0·96 (95% Cl 0·74–1·24; p=0·7). Similarly, no significant differences were seen between donepezil and placebo in behavioural and psychological symptoms, carer psychopathology, formal care costs, unpaid caregiver time, adverse events or deaths, or between 5 mg and 10 mg donepezil.InterpretationDonepezil is not cost effective, with benefits below minimally relevant thresholds. More effective treatments than Cholinesterase inhibitors are needed for Alzheimer's disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
珂婷发布了新的文献求助10
刚刚
任性孤兰完成签到,获得积分10
1秒前
susu_发布了新的文献求助10
1秒前
haoliu完成签到,获得积分10
1秒前
1秒前
呀呀呀呀完成签到,获得积分10
2秒前
香蕉饼干发布了新的文献求助10
7秒前
张若旸完成签到,获得积分10
9秒前
如初完成签到 ,获得积分10
10秒前
10秒前
西兰花的科研小助手完成签到,获得积分10
16秒前
无尘发布了新的文献求助10
17秒前
17秒前
灯灯完成签到,获得积分10
18秒前
珂婷完成签到,获得积分10
18秒前
嗯哼应助xyjf15采纳,获得30
20秒前
纪震宇发布了新的文献求助10
21秒前
魔幻灯泡发布了新的文献求助10
21秒前
23秒前
LJJZZX完成签到,获得积分20
24秒前
星辰大海应助周青春偶像采纳,获得10
27秒前
29秒前
大模型应助睡不醒的xx采纳,获得10
29秒前
纪震宇完成签到,获得积分10
30秒前
NexusExplorer应助活泼新儿采纳,获得10
30秒前
32秒前
33秒前
35秒前
sks关注了科研通微信公众号
36秒前
汉堡包应助光芒万丈采纳,获得10
38秒前
科研发布了新的文献求助100
39秒前
showitt发布了新的文献求助10
40秒前
Z_Z完成签到,获得积分10
41秒前
42秒前
KYTZL发布了新的文献求助10
42秒前
zhanks发布了新的文献求助10
45秒前
爆米花应助科研通管家采纳,获得10
47秒前
SciGPT应助科研通管家采纳,获得10
47秒前
47秒前
47秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3055401
求助须知:如何正确求助?哪些是违规求助? 2712227
关于积分的说明 7430195
捐赠科研通 2357037
什么是DOI,文献DOI怎么找? 1248528
科研通“疑难数据库(出版商)”最低求助积分说明 606737
版权声明 596093